Newborn biobetter, biosimilar maker Mabpharm pitches the latest biotech IPO in Hong Kong
The latest biotech to IPO in Hong Kong didn’t exist three months ago.
To be sure, the team that is now at Mabpharm has been working on their three “core products” — so called biobetters of well-known monoclonal antibodies — since 2015 through a company called Sinomab. Its founder and owner, Guo Jianjun, spun Mabpharm out in June to separate the drug development business from Sinomab’s CRO and CMO services.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
